Forbes October 11, 2024
Sylvain Duranton

Just two years ago, the arrival of ChatGPT sent ripples through the technological landscape, stirring visions of the internet’s disruptive dawn in the early 2000s.

By April 2023, Goldman Sachs was heralding GenAI’s potential in an exuberant piece titled “Generative AI Could Raise Global GDP by 7%.” Bank of America echoed this optimism, forecasting a staggering $15.7 trillion stimulus from GenAI by 2030. Startups rode this wave of enthusiasm: within a year of its inception, France’s Mistral AI was valued at $6.6 billion, while its American rival, Anthropic, soared to $15.6 billion.

Yet, as swiftly as the optimism surged, skepticism has begun to surface. In June, Goldman Sachs, in a shift of tone, published “GenAI: Too Much Spend, Too Little...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Technology
Google digs deeper into healthcare AI: 5 notes
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
How AI Has And Will Continue To Transform Healthcare
AI Translates Nature into New Medicines | StartUp Health Insights: Week of Nov 26, 2024
Building AI trust: The key role of explainability

Share This Article